The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Ascending
Feb 2020
Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism
Addiction
AUTHOR(S)
Mar 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Apr 2020
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study
The Journal of Clinical Psychiatry
AUTHOR(S)
May 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT/QTc study
Progress in Neuro-Psychopharmacology & Biological Psychiatry
AUTHOR(S)
May 2020
Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia
CNS Spectrums
AUTHOR(S)
Jun 2020
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
The American Journal on Addictions
AUTHOR(S)
Jun 2020
Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey
BMC Psychiatry
AUTHOR(S)
Jul 2020
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Aug 2020
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
CNS Drugs
AUTHOR(S)
Sep 2020
Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey
Patient Preference and Adherence
AUTHOR(S)
